A phase IA, open-label, dose escalation study of patupilone administered intravenously every 3 weeks in adult patients with advanced solid tumors.
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2015
At a glance
- Drugs Patupilone (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 28 May 2010 Actual patient number (15) added as reported by ClinicalTrials.gov.
- 28 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 May 2010 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.